Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome (a Double-blind Placebo-parallel Group Trial)

Trial Profile

Effect of Ivabradine on Patients With Postural Orthostatic Tachycardia Syndrome (a Double-blind Placebo-parallel Group Trial)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 31 Oct 2018

At a glance

  • Drugs Ivabradine (Primary)
  • Indications Postural orthostatic tachycardia syndrome
  • Focus Therapeutic Use
  • Acronyms POTS
  • Most Recent Events

    • 22 Oct 2018 Planned End Date changed from 1 Jun 2018 to 1 Jun 2019.
    • 22 Oct 2018 Planned primary completion date changed from 1 Jun 2018 to 1 Feb 2019.
    • 13 Mar 2018 The dosage of the drug has changed from 1 pill once a day to 1 pill twice a day
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top